Alghanem Bandar, Mansour Fatmah A, Shaibah Hayat, Almuhalhil Khawlah, Almourfi Feras, Alamri Hassan S, Alajmi Hala, Rashid Mamoon, Alroqi Fayhan, Jalouli Maroua, Harrath Abdel Halim, Boudjellal Mohammad, Barhoumi Tlili
Medical Research Core Facility and Platforms, King Abdullah International Medical Research Centre, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Heliyon. 2023 Apr;9(4):e15224. doi: 10.1016/j.heliyon.2023.e15224. Epub 2023 Apr 9.
Treatment of severe cases of coronavirus disease 2019 (COVID-19) is extremely important to minimize death and end-organ damage. Here we performed a proteomic analysis of plasma samples from mild, moderate and severe COVID-19 patients. Analysis revealed differentially expressed proteins and different therapeutic potential targets related to innate immune responses such as fetuin-A, tetranectin (TN) and paraoxonase-1 (PON1). Furthermore, protein changes in plasma showed dysregulation of complement and coagulation cascades in COVID-19 patients compared to healthy controls. In conclusion, our proteomics data suggested fetuin-A and TN as potential targets that might be used for diagnosis as well as signatures for a better understanding of the pathogenesis of COVID-19 disease.
治疗2019冠状病毒病(COVID-19)重症病例对于将死亡和终末器官损伤降至最低极为重要。在此,我们对轻症、中症和重症COVID-19患者的血浆样本进行了蛋白质组学分析。分析揭示了与天然免疫反应相关的差异表达蛋白以及不同的治疗潜在靶点,如胎球蛋白-A、四连蛋白(TN)和对氧磷酶-1(PON1)。此外,与健康对照相比,COVID-19患者血浆中的蛋白质变化显示补体和凝血级联反应失调。总之,我们的蛋白质组学数据表明,胎球蛋白-A和TN作为潜在靶点,可用于诊断以及更好地理解COVID-19疾病发病机制的标志物。